BHV - Latest News
BlackRock Virginia Municipal Bond Trust (BHV), operates in Financial Services / Asset Management - Bonds, trades on NYSE.
Market capitalization stands near $18.0M.
The article list below shows the most recent BHV headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent BHV Headlines
Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
prnewswire.com - Oct 8, 2026
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member st
Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
prnewswire.com - Sep 28, 2026
Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Sy
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV) Shares Pass Below 50 Day Moving Average – Here’s What Happened
defenseworld.net - Sep 5, 2026
BlackRock Virginia Municipal Bond Trust (NYSEAMERICAN:BHV - Get Free Report)'s share price crossed below its fifty day moving average during trading o
Biohaven: Buy Reiterated On Opakalim License Agreement For Epilepsy And More
seekingalpha.com - Aug 27, 2026
Biohaven Ltd. maintains a Buy rating, driven by pivotal trial progress in protein degraders and a key licensing deal for its Kv7 platform with SK Bio
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
prnewswire.com - Aug 10, 2026
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individua
Frequently asked BHV news questions
- What is the latest BHV news headline?
- The most recent BHV headline (Oct 8, 2026) is "Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the BHV news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What BHV news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual BHV options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.